|
Schizophrenia
|
0.410 |
GeneticVariation
|
disease |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Schizophrenia
|
0.410 |
Biomarker
|
disease |
PSYGENET |
Subsequent real-time PCR has shown that mRNA for muscleblind protein 1 (MBNL1) and protocadherin 17 (PCDH17) are increased in BA 46 from subjects with schizophrenia of short, but not long, duration.
|
17464717 |
2007 |
|
Schizophrenia
|
0.410 |
Biomarker
|
disease |
BEFREE |
Subsequent real-time PCR has shown that mRNA for muscleblind protein 1 (MBNL1) and protocadherin 17 (PCDH17) are increased in BA 46 from subjects with schizophrenia of short, but not long, duration.
|
17464717 |
2007 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways.
|
31374203 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence.
|
29326435 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study showed that the protocadherin 17 (<i>PCDH17</i>) gene was frequently methylated and functioned as a tumor suppressor in CRC.
|
31815010 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protocadherin 17 is a tumor suppressor and is frequently methylated in nasopharyngeal carcinoma.
|
30863170 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Intelligence
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function.
|
29844566 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Subsequent gene expression analysis of PCDH17 revealed decreased expression in all of the tumor samples in comparison to the control ones.
|
29991130 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We identified recurrent elevation of PCDH17 promoter DNA methylation in 32/81 (40%) primary tumors (P < 0.001) and therein hypermethylation of 12 (15%) cases in contrast to no tumor controls (n = 24) that were all unmethylated.
|
29566279 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BACKGROUND Current studies indicated that PCDH17 functions as a tumor suppressor, which is frequently inactivated by aberrant promoter methylation in urologic tumors.
|
28688232 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that PCDH17 was frequently downregulated or silenced in 78% (7/9) of breast tumor cell lines, as well as 89% (32/36) of primary tumors.
|
27351130 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues.
|
26404644 |
2015 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.
|
24567353 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PCDH17 methylation in tumor samples after radical prostatectomy may be used as an independent prognostic biomarker.
|
25091018 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, PCDH17 acts as a tumour suppressor, exerting its anti-proliferative activity through inducing apoptosis and autophagy, and is frequently silenced in gastric and colorectal cancers.
|
22926751 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We focused on it as a candidate tumor suppressor gene (TSG) and hypothesized that PCDH17 may be susceptible to promoter methylation and gene silencing.
|
22207556 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
|
21213369 |
2011 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
These results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs.
|
20200074 |
2010 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer.
|
31772653 |
2019 |
|
Bladder Neoplasm
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer.
|
31772653 |
2019 |
|
Carcinoma of bladder
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer.
|
31772653 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
Biomarker
|
disease |
BEFREE |
The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups.
|
26700620 |
2016 |
|
Bladder Neoplasm
|
0.050 |
Biomarker
|
disease |
BEFREE |
The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups.
|
26700620 |
2016 |